AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33802283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 32216456 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 609
Study 32216456 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 609
Study 32216456 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (combined dose group)
Number of subjects: 609
Study 32216456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 35623844 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH mycoprotein (nucleotide-rich)
Number of subjects: 20
Study 35623844 — intervention group
Group type: COMPARATOR
Intervention: LOW mycoprotein (nucleotide-depleted)
Number of subjects: 20
Study 34019724 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning cultural competence intervention
Number of subjects: 113
Study 32479328 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT-Dyad
Number of subjects: 42
Study 32479328 — intervention group
Group type: COMPARATOR
Intervention: ETAU
Number of subjects: 42
Study 36203818 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Erector Spinae Plane Block (CESPB)
Number of subjects: 120
Study 36203818 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Patient-Controlled Opioid Analgesia (PCIA)
Number of subjects: 120
Study 36203818 — intervention group
Group type: EXPERIMENTAL
Intervention: CESPB
Number of subjects: 120
Study 34002265 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexvix® TURB with immediate ICT only (n=67, 40 mg Mitomycin)
Number of subjects: 129
Study 34002265 — intervention group
Group type: COMPARATOR
Intervention: white-light TURB with immediate ICT followed by maintenance ICT (n=62, 20 mg Mitomycin weekly for 6 weeks, then 20 mg/month for 6 months)
Number of subjects: 129
Study 36269714 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HR (three months of daily isoniazid plus rifampicin)
Number of subjects: 225
Study 36269714 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP (three months of once-weekly isoniazid plus rifapentine)
Number of subjects: 225
Study 36269714 — intervention group
Group type: EXPERIMENTAL
Intervention: 4R (four months of daily rifampicin)
Number of subjects: 225
Study 34800298 — intervention group
Group type: COMPARATOR
Intervention: IPSRT (Interpersonal and Social Rhythm Therapy)
Number of subjects: 68
Study 34800298 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSRT-CR (IPSRT with Cognitive Remediation)
Number of subjects: 68
Study 34800298 — intervention group
Group type: COMPARATOR
Intervention: IPSRT
Number of subjects: 68
Study 34800298 — intervention group
Group type: COMPARATOR
Intervention: IPSRT vs IPSRT-CR
Number of subjects: 68
Study 32152482 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure less than 130/80 mmHg
Number of subjects: 447
Study 32152482 — intervention group
Group type: EXPERIMENTAL
Intervention: baPWV above 1731 cm/s
Number of subjects: 447
Study 35762913 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) at 60% of maximal inspiratory pressure (MIP) for 8 weeks
Number of subjects: 26
Study 35762913 — intervention group
Group type: COMPARATOR
Intervention: Sham IMT at 15% of maximal inspiratory pressure (MIP) for 8 weeks
Number of subjects: 26
Study 32248506 — intervention group
Group type: EXPERIMENTAL
Intervention: Skull thickness measurements at various sites (midline anterior, midline posterior, right lateral, left lateral, antero-lateral, postero-lateral)
Number of subjects: 270
Study 32248506 — intervention group
Group type: EXPERIMENTAL
Intervention: Skull thickness measurements at the end of growth
Number of subjects: 270
Study 32248506 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for pin tip size based on age
Number of subjects: 270
Study 32248506 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in skull thickness in children aged <4 years
Number of subjects: 270
Study 32586344 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 200
Study 32586344 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (Control)
Number of subjects: 200
Study 37256485 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ophthalmic drops (Latilactobacillus sakei)
Number of subjects: 40
Study 37256485 — intervention group
Group type: COMPARATOR
Intervention: Placebo ophthalmic drops
Number of subjects: 40
Study 37256485 — intervention group
Group type: EXPERIMENTAL
Intervention: Active oral capsules (Latilactobacillus sakei)
Number of subjects: 40
Study 37256485 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral capsules
Number of subjects: 40
Study 33660668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclinic-based adolescent behavioral weight control treatment delivered by YMCA coaches
Number of subjects: 66
Study 32508129 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-month home exercise program with one-hour sessions delivered by a physiotherapist
Number of subjects: 60
Study 32508129 — intervention group
Group type: COMPARATOR
Intervention: Minimal education about shoulder condition and instructions to continue activities as normal
Number of subjects: 60
Study 35940835 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multimodal prehabilitation (exercise and nutrition) for >3 weeks
Number of subjects: 750
Study 35940835 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 750
Study 34420228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 29
Study 34420228 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 29
Study 32774567 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration series with techniques such as sphenopalatine ganglion (SPG) block and ganglionic local opioid analgesia (GLOA)
Number of subjects: 83
Study 36297022 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalosides supplementation (4 mg per day for 7 days)
Number of subjects: 11
Study 36297022 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalosides supplementation
Number of subjects: 11
Study 36297022 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 11
Study 32170553 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 220
Study 35986579 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, supported eTherapy (four-session program)
Number of subjects: 19
Study 35986579 — intervention group
Group type: EXPERIMENTAL
Intervention: Program feasibility
Number of subjects: 19
Study 36254133 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tPBM (5 sessions of 850 nm)
Number of subjects: 42
Study 32482519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg SR orally twice daily)
Number of subjects: 12
Study 32482519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 34968119 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent positive psychology intervention
Number of subjects: 141
Study 34968119 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 141
Study 34028623 — intervention group
Group type: EXPERIMENTAL
Intervention: All-inside tibial socket preparation (Group 2)
Number of subjects: 80
Study 34028623 — intervention group
Group type: COMPARATOR
Intervention: Complete tibial tunnel technique (Group 1)
Number of subjects: 80
Study 34028623 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrupled semitendinosus tendon graft
Number of subjects: 80
Study 32585354 — intervention group
Group type: EXPERIMENTAL
Intervention: HD BP BL ECT
Number of subjects: 0
Study 34397389 — intervention group
Group type: EXPERIMENTAL
Intervention: IMP‐FITNET
Number of subjects: 244
Study 34397389 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 244
Study 34709880 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adapted postinduction approach
Number of subjects: 807
Study 34709880 — intervention group
Group type: COMPARATOR
Intervention: Standard rituximab maintenance (RM)
Number of subjects: 807
Study 34768520 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial induction therapy (MIT)
Number of subjects: 22
Study 34768520 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulated pulsed shortwave therapy)
Number of subjects: 22
Study 34218684 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated ivermectin mass drug administrations
Number of subjects: 0
Study 34218684 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equations with small sample corrections
Number of subjects: 0
Study 34218684 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover design
Number of subjects: 0
Study 34218684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-level analyses and individual-level analyses
Number of subjects: 0
Study 32600389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/d folic acid
Number of subjects: 36
Study 32600389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 36142006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantra meditation alone (MA)
Number of subjects: 42
Study 36142006 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation plus physical yoga (MY)
Number of subjects: 42
Study 36142006 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation plus ethical education (ME)
Number of subjects: 42
Study 36142006 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation plus yoga and ethical education (MYE)
Number of subjects: 42
Study 34666808 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen (HFNO) with FiO2 0.35, flow 50 LPM, temperature 34 °C
Number of subjects: 22
Study 34666808 — intervention group
Group type: COMPARATOR
Intervention: Low flow nasal oxygen (LFNO) 5 LPM
Number of subjects: 22
Study 35020026 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic growth factors
Number of subjects: 120
Study 35020026 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study 34547824 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained crowns
Number of subjects: 41
Study 34547824 — intervention group
Group type: COMPARATOR
Intervention: Cemented crowns
Number of subjects: 41
Study 34547824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 35715450 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (a selective-serotonin-reuptake inhibitor)
Number of subjects: 0
Study 35715450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32628258 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP video program
Number of subjects: 9935
Study 32628258 — intervention group
Group type: COMPARATOR
Intervention: Control (usual ACP practices)
Number of subjects: 9935
Study 34606832 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% asivatrep cream
Number of subjects: 240
Study 34606832 — intervention group
Group type: COMPARATOR
Intervention: Vehicle group
Number of subjects: 240
Study 33631066 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg, single intravenous infusion, with a possible second dose 8 to 24 hours later)
Number of subjects: 438
Study 33631066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 33631066 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 438
Study 32762672 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exogenous surfactant (20 mg/kg)
Number of subjects: 44
Study 35188554 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline implementation strategies at the cluster, health professional, and patient levels
Number of subjects: 688
Study 35188554 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no intervention)
Number of subjects: 688
Study 32810929 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of breast density (non-dense breast)
Number of subjects: 1609
Study 32810929 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of breast density (dense breast)
Number of subjects: 1609
Study 32810929 — intervention group
Group type: EXPERIMENTAL
Intervention: Good breast density knowledge
Number of subjects: 1609
Study 32810929 — intervention group
Group type: COMPARATOR
Intervention: Unawareness of breast density
Number of subjects: 1609
Study 32810929 — intervention group
Group type: COMPARATOR
Intervention: Poor breast density knowledge
Number of subjects: 1609
Study 34147041 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg capsules of Berberis vulgaris extract, twice daily for 4 weeks
Number of subjects: 52
Study 34147041 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of starch capsules (placebo), twice daily for 4 weeks
Number of subjects: 52
Study 32364800 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants preferred a psychotherapist with personality characteristics similar to their own.
Number of subjects: 0
Study 36153586 — intervention group
Group type: EXPERIMENTAL
Intervention: RinasciMENTE program (Internet-based self-help intervention based on CBT principles)
Number of subjects: 128
Study 36153586 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 128
Study 32037857 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic exercise rehabilitation
Number of subjects: 166
Study 32037857 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 166
Study 32037857 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 166
Study 32037857 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 166
Study 32223373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 439
Study 32223373 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications (MEDs)
Number of subjects: 439
Study 32223373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and MEDs (COMB)
Number of subjects: 439
Study 32223373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 36102464 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance tape (PT) with home exercise program for 4 weeks
Number of subjects: 39
Study 36102464 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic tape (CT) with home exercise program for 4 weeks
Number of subjects: 39
Study 36102464 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) with home exercise program for 4 weeks
Number of subjects: 39
Study 34727951 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (AP)
Number of subjects: 1420
Study 34727951 — intervention group
Group type: COMPARATOR
Intervention: No postoperative antibiotic prophylaxis (AP)
Number of subjects: 1420
Study 32947390 — intervention group
Group type: EXPERIMENTAL
Intervention: Umezu polyphenols (800 mg/day for 12 weeks)
Number of subjects: 72
Study 32947390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 32947390 — intervention group
Group type: EXPERIMENTAL
Intervention: Umezu polyphenols
Number of subjects: 72
Study 35288332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract (500 mg/d flavanols, including 80 mg (−)‐epicatechin) and multivitamin (Centrum Silver©)
Number of subjects: 21442
Study 35288332 — intervention group
Group type: COMPARATOR
Intervention: Cocoa extract and multivitamin placebo
Number of subjects: 21442
Study 35288332 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin and cocoa extract placebo
Number of subjects: 21442
Study 35288332 — intervention group
Group type: COMPARATOR
Intervention: Both placebos
Number of subjects: 21442
Study 33417035 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 37
Study 33417035 — intervention group
Group type: EXPERIMENTAL
Intervention: MI
Number of subjects: 37
Study 33417035 — intervention group
Group type: COMPARATOR
Intervention: NMES + MI
Number of subjects: 37
Study 33417035 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study 33004061 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria elimination readiness assessment (MERA)
Number of subjects: 35
Study 33004061 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for health providers (HPs)
Number of subjects: 35
Study 33004061 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests (RDTs) availability
Number of subjects: 35
Study 33004061 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health volunteers (CHVs) responsibilities
Number of subjects: 35
Study 33004061 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of anti-malarials among CHVs
Number of subjects: 35
Study 33004061 — intervention group
Group type: EXPERIMENTAL
Intervention: Data management and use
Number of subjects: 35
Study 33004061 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for malaria among patients with fever
Number of subjects: 35
Study 35215483 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based and family-based interventions with monthly monitoring for two consecutive semesters
Number of subjects: 0
Study 35215483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific interventions)
Number of subjects: 0
Study 35215483 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based and family-based interventions
Number of subjects: 0
Study 35109633 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention; 31 dyads used telehealth methods to access the program.
Number of subjects: 63
Study 35109633 — intervention group
Group type: COMPARATOR
Intervention: In-home visits; 32 dyads received visits in their own home.
Number of subjects: 63
Study 32629391 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab (BE)
Number of subjects: 0
Study 32629391 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone (E)
Number of subjects: 0
Study 35532113 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom mandibular advancement device (MAD) applied for 12 weeks
Number of subjects: 58
Study 35532113 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncustom mandibular advancement device (MAD) applied for 12 weeks
Number of subjects: 58
Study 35532113 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported outcomes for both custom and noncustom MADs
Number of subjects: 58
Study 33417728 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DTI parameters from 24 white matter tracts (WMTs)
Number of subjects: 208
Study 33417728 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral uncinate fasciculus
Number of subjects: 208
Study 33417728 — intervention group
Group type: EXPERIMENTAL
Intervention: Other WMTs in cingulum, cerebral and cerebellar peduncle, internal capsule, and corpus callosum
Number of subjects: 208
Study 33865928 — intervention group
Group type: EXPERIMENTAL
Intervention: ENGAGE (engagement-focused behavioral therapy)
Number of subjects: 854
Study 33865928 — intervention group
Group type: COMPARATOR
Intervention: UC (community-based usual care)
Number of subjects: 854
Study 33865928 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent medication use during behavioral therapy
Number of subjects: 854
Study 33865928 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD+internalizing clinical profile
Number of subjects: 854
Study 33865928 — intervention group
Group type: EXPERIMENTAL
Intervention: Family adversity
Number of subjects: 854
Study 33865928 — intervention group
Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 854
Study 33412570 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (booklets on sleep apnea and sleep test)
Number of subjects: 104
Study 33412570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 104
Study 33316634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 1977
Study 33316634 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 1977
Study 33316634 — intervention group
Group type: COMPARATOR
Intervention: CNS relapse
Number of subjects: 1977
Study 33316634 — intervention group
Group type: COMPARATOR
Intervention: Overall survival post-relapse
Number of subjects: 1977
Study 33316634 — intervention group
Group type: COMPARATOR
Intervention: Risk factors for CNS recurrence
Number of subjects: 1977
Study 35571469 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone + N-acetyl cysteine (NAC)
Number of subjects: 768
Study 35571469 — intervention group
Group type: COMPARATOR
Intervention: Simethicone alone
Number of subjects: 768
Study 35571469 — intervention group
Group type: COMPARATOR
Intervention: N-acetyl cysteine (NAC) alone
Number of subjects: 768
Study 35571469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study 35248186 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg twice per day
Number of subjects: 2044
Study 35248186 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 15 mg twice per day
Number of subjects: 2044
Study 35248186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2044
Study 32889633 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR-guided PCI
Number of subjects: 84
Study 32889633 — intervention group
Group type: COMPARATOR
Intervention: OCT-guided PCI
Number of subjects: 84
Study 32889633 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 84
Study 33344050 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dorzolamide for 3 months
Number of subjects: 33
Study 33344050 — intervention group
Group type: COMPARATOR
Intervention: Observed controls (no active intervention)
Number of subjects: 33
Study 33464334 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy alone (n=101)
Number of subjects: 204
Study 33464334 — intervention group
Group type: COMPARATOR
Intervention: Combined intravenous thrombolysis (alteplase at 0.6 mg/kg) plus mechanical thrombectomy (n=103)
Number of subjects: 204
Study 33464334 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy alone
Number of subjects: 204
Study 33464334 — intervention group
Group type: COMPARATOR
Intervention: Combined intravenous thrombolysis plus mechanical thrombectomy
Number of subjects: 204
Study 32164544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle-based eHealth intervention
Number of subjects: 15